QR kód

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). It is also used as an appropriate treatment of chronic myelomonocytic leukemia (CMML) in the real life setting. As treat...

Celý popis

Uloženo v:
Hlavní autoři: Nikolova D., Yordanov A., Radinov A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Sciendo 2021-10-01
Edice:Acta Medica Bulgarica
Témata:
azacitidine (aza, vidaza®)
monitoring
blood count parameters
toxicity
cytogenetic findings
On-line přístup:https://doi.org/10.2478/amb-2021-0030
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky